The models predicted that the effect size for 11C-(R)-PK11195 to identify a 50% difference in TSPO level is about 1, which is consistent with in vivo findings such as in Tomasi et al. (2008), where 11C-(R)-PK11195 was used to characterise Alzheimer's disease. This evidence concerns the gene TSPO and Alzheimer disease.